Dual GIP/GLP-1 Receptor Agonist — Mounjaro / Zepbound
A first-in-class dual agonist of both GIP and GLP-1 receptors, developed by Eli Lilly. FDA-approved for type 2 diabetes (Mounjaro, 2022) and obesity (Zepbound, 2023), tirzepatide produces greater weight loss than any previously approved medication — averaging 20–22% in clinical trials. The SURMOUNT-5 trial confirmed it outperforms semaglutide directly, positioning it as the current gold standard in pharmacological weight management.
01 — Research Summary
Tirzepatide has generated one of the most impressive clinical evidence packages in the history of metabolic medicine. The SURPASS programme for diabetes and SURMOUNT programme for obesity have collectively established it as the most effective approved weight loss medication ever studied.
Tirzepatide superior: −20.2% vs −13.7% weight loss. The NEJM-published SURMOUNT-5 trial directly compared tirzepatide and semaglutide at maximum tolerated doses in adults with obesity but without diabetes. Tirzepatide produced 47% more weight loss — definitively establishing its superiority for body weight reduction.
Average 20.9% body weight reduction at 15mg. The landmark obesity trial showed tirzepatide 15mg produced 20.9% average weight loss over 72 weeks, with 57% of participants losing more than 20% of body weight — results previously only seen with bariatric surgery.
Sustained 21% weight loss maintained at 88 weeks. The maintenance trial showed that participants who lost weight on tirzepatide and continued treatment maintained an average 21% weight reduction at 88 weeks — with significant regain in those switched to placebo, confirming the need for ongoing treatment.
Superior HbA1c reduction and weight loss vs semaglutide 1mg. In type 2 diabetes, tirzepatide outperformed semaglutide 1mg on both HbA1c reduction and weight loss across all three doses tested — the first compound to beat semaglutide head-to-head in a major trial.
02 — Mechanism of Action
Tirzepatide's key advantage over semaglutide is its dual mechanism — activating both GLP-1 and GIP receptors simultaneously. The GIP component appears to amplify the metabolic effects of GLP-1 receptor agonism in ways that aren't fully understood, but result in meaningfully greater weight loss.
Tirzepatide is a single molecule that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This is fundamentally different from semaglutide, which only targets GLP-1. The GIP component was initially expected to worsen outcomes but turns out to amplify the benefits.
Both receptor pathways drive glucose-dependent insulin secretion and glucagon suppression, with the dual agonism producing stronger glycaemic control than either pathway alone. The glucose-dependence of this mechanism minimises hypoglycaemia risk.
The combination of GIP and GLP-1 receptor activation in the hypothalamus and brainstem produces stronger appetite suppression than GLP-1 alone — the primary reason tirzepatide produces greater weight loss than semaglutide at comparable dose frequencies.
GIP receptors are expressed directly on fat cells, and tirzepatide's GIP agonism appears to improve fat metabolism and reduce fat storage in ways that GLP-1 agonism alone doesn't achieve. This adipose tissue effect may contribute to the superior body composition outcomes.
Like semaglutide, tirzepatide slows gastric emptying and extends post-meal satiety. The magnitude of gastric slowing is somewhat less than semaglutide at comparable doses, which may explain the lower rate of nausea reported with tirzepatide despite its greater efficacy.
Both work. Tirzepatide produces more weight loss on average — 20%+ vs 15% — with comparable or slightly better tolerability. Semaglutide has a longer track record and more real-world data. Cost is similar. If weight loss is the primary goal and access to either is possible, the clinical evidence favours tirzepatide. If cardiovascular risk reduction is the primary goal, semaglutide's SELECT trial data is more established.
03 — Dosing Protocols
Tirzepatide uses the same mandatory escalation approach as semaglutide. The escalation schedule is critical — jumping to higher doses significantly increases GI side effects and discontinuation rates.
| Protocol | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Escalation Phase 1 | 2.5 mg/week | 4 weeks | Initiation | Starting dose. Not therapeutic — tolerance building only. |
| Escalation Phase 2 | 5 mg/week | 4 weeks | Weeks 5–8 | First potentially therapeutic dose. Some weight loss begins here. |
| Escalation Phase 3 | 7.5 mg/week | 4 weeks | Weeks 9–12 | Continued escalation if tolerating well. |
| Escalation Phase 4 | 10 mg/week | 4 weeks | Weeks 13–16 | Higher efficacy dose — most patients see meaningful weight loss here. |
| Escalation Phase 5 | 12.5 mg/week | 4 weeks | Weeks 17–20 | Near-maximum dose. |
| Maximum dose | 15 mg/week | Ongoing | Week 21+ | Maximum approved dose. Used in SURMOUNT trials — 20%+ average weight loss. |
GI side effects (nausea, vomiting, diarrhoea) are common during escalation but generally less frequent than with semaglutide at equivalent efficacy doses. Muscle loss occurs without adequate protein intake and resistance training — 1.6g/kg protein minimum is recommended. Compounded tirzepatide availability has been restricted following FDA shortage resolution in early 2025 — verify current legal status in your jurisdiction.
04 — Community Experiences
Tirzepatide has rapidly overtaken semaglutide as the most discussed GLP-1 compound in online communities, driven by the dramatic SURMOUNT trial results and the head-to-head superiority data. r/Tirzepatide has become one of the fastest-growing health communities on Reddit. Key themes: the weight loss results are consistently described as more dramatic than semaglutide; side effects are perceived as somewhat milder; and the community extensively debates whether the cost premium over semaglutide is justified.
These are user-reported experiences from public forums. Not endorsed by Whats That Peptide and should not be interpreted as clinical evidence. Individual results vary. Always consult a healthcare professional.
"Started at 130kg. Now 102kg. The first 3 months were slow. Months 4–9 the weight just fell off. I barely think about food now. I eat when I'm hungry, stop when I'm full — I've never experienced that before in my life..."
"Ran semaglutide for 6 months, lost 9kg. Switched to tirzepatide, lost another 14kg in the next 6 months. The difference in appetite suppression is real. Tirzepatide is stronger. The side effects were actually milder for me too..."
"Nausea was rough at 10mg. I stayed at 7.5mg for 8 weeks instead of 4 before escalating and the difference was significant. Don't rush the escalation schedule — the plateau in escalation is worth it..."
"Had DEXA before and after 6 months. Lost 18kg total. 14kg fat, 4kg lean mass. The lean mass loss is real and you have to fight it. 160g protein per day and 3x lifting per week is non-negotiable on tirzepatide..."